Q3 2024 EPS Estimates for Moderna, Inc. (NASDAQ:MRNA) Decreased by Zacks Research

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Zacks Research reduced their Q3 2024 EPS estimates for Moderna in a research note issued to investors on Tuesday, October 15th. Zacks Research analyst S. Ganoria now forecasts that the company will post earnings of ($1.88) per share for the quarter, down from their prior estimate of ($1.83). The consensus estimate for Moderna’s current full-year earnings is ($9.85) per share. Zacks Research also issued estimates for Moderna’s Q4 2024 earnings at ($1.79) EPS, FY2024 earnings at ($10.07) EPS, Q1 2025 earnings at ($2.90) EPS, Q2 2025 earnings at ($3.11) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($8.70) EPS, Q1 2026 earnings at ($2.68) EPS, Q2 2026 earnings at ($2.76) EPS, Q3 2026 earnings at ($0.72) EPS and FY2026 earnings at ($6.00) EPS.

Several other research firms have also commented on MRNA. The Goldman Sachs Group reduced their price target on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 target price on shares of Moderna in a research note on Thursday, June 27th. Bank of America dropped their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Jefferies Financial Group reduced their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $99.81.

Moderna Stock Performance

NASDAQ MRNA opened at $57.46 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock’s fifty day moving average is $71.95 and its two-hundred day moving average is $105.27. The firm has a market capitalization of $22.02 billion, a P/E ratio of -3.67 and a beta of 1.66. Moderna has a fifty-two week low of $55.70 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the previous year, the firm posted ($3.62) EPS. The business’s revenue for the quarter was down 29.9% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC acquired a new stake in shares of Moderna in the 4th quarter valued at $206,000. HighPoint Advisor Group LLC purchased a new position in Moderna in the fourth quarter valued at $491,000. Los Angeles Capital Management LLC acquired a new stake in Moderna in the first quarter valued at $2,693,000. GAMMA Investing LLC lifted its holdings in Moderna by 37.8% during the 1st quarter. GAMMA Investing LLC now owns 2,994 shares of the company’s stock worth $319,000 after buying an additional 822 shares during the last quarter. Finally, Mather Group LLC. acquired a new position in shares of Moderna during the 1st quarter worth about $57,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,184 shares of company stock worth $3,804,931 in the last ninety days. 15.70% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.